Peganum harmala: Eine Literaturzusammenstellung

Unterthema "Harmala-roth"

Zum Rot Faerben mit Nasturstoffen verwendete man in der Tuerkei, Indien u.a. die rote Farbe der Steppenraute.

• GOEBEL Fr.: "Ueber das Harmalin von Fr. Goebel in Dorpat", In: Liebigs Annalen der Chemie und Pharmacie, Heidelberg, Bd. 38, Heft 3, S. 363-366, 1841.
• Johann Gottfried Dingler (Hg.): Polytechnisches Journal, Band 81, Stuttgart, 1841: enthaelt: GOEBEL Fr.: "LXXIII. Ueber das Harmalin, den Farbstoff der Harmelraute", Heft 3, S. 305-306, 1841.
• Eine im Netz gefundene OCR-Version des Textes von Goebel

Geschichte und Kultur:

• FLATTERY David S., SCHWARTZ Martin: "Haoma and Harmaline. The Botanical Identity of the Indo-Iranian Sacred Hallucinogen 'Soma' and its Legacy in Religion, Language, and Middle Eastern Folklore.", Near Eastern Studies, Volume 21, University of California Press, 1989. fragm.

Extraktion und Identifikation der Alkaloide und Wirkstoffe:

• Journal fuer praktische Chemie, Jahrgang 1847, Band 42. (ab Seite 296 im PDF ist "Untersuchungen ueber die Samen von Peganum harmala, von J. Fritsche, Fortsetzung von Bd. 41")

Spezifische Untersuchungen zu den einzelnen Alkaloiden und Pflanzen, die diese enthalten:

• NARANJO Plutarco: "Estudio comparativo de la Harmina, la Dietilamida del acido Lisergico (LSD 25) y la Mescalina", Rev.Confed.med.panamer., Vol. 6, S. 1-8, (1959).
• OTT Jonathan: "Ayahuasca Analogues.", Werbung.
• OTT Jonathan: "Pharmahuasca, Anahuasca and Vinho da Jurema: Human Pharmacology of Oral DMT Plus Harmine", S. 1-13, Yearbook for Ethnomedicine 1997/98.
• SCHULTES R.E: "The beta-Carbonline Hallucinogens of South America", Journal of Psychoactive Drugs, Vol. 14 (No. 3), S. 205-220, Jul.-Sep., 1982.

Medizinisch-pharmazeutische Wirkungen der Pflanze und ihrer Alkaloide und Einsatzgebiete:

• ARSHAD N. et al.: "Peganum harmala Can Minimize Escherichia coli Infection in Poultry, but Long-Term Feeding May Induce Side Effects", IMMUNOLOGY, HEALTH, AND DISEASE.
• JIMENEZ Judith, RIVERON-NEGRETE Leticia, ABDULLAEV Fikrat, ESPINOSA-AGUIRRE Javier, RODRIGUEZ-ARNAIZ Rosario: "Cytotoxicity of the beta-carboline alkaloids harmine and harmaline in human cell assays in vitro", Experimenltal and Toxicologic Pathology: 60 (2008) S. 381-389.
• MIRZAIE M. et al.: "Antileishmanial activity of Peganum harmala extract on the in vitro growth of Leishmania major promastigotes in comparison to a trivalent antimony drug"
• MONSEF H.R. et al.: "Antinociceptive effects of Peganum harmala L. alkaloid extract on mouse formalin test"
• MOURA Dinara Jaqueline et al.: "Antioxidant properties of beta-carboline alkaloids are related to their antimutagenic and antigenotoxic activities", Mutagenesis, Vol. 22, Nr. 4, S. 293–302, 2007.
• REZA Verdian Rizi Mohammed, ABBAS Hadjiakhoondi: "Cytotoxity and Antimicrobial Activity of Harman Alkaloids", Journal of Pharmacology and Toxicology, 2(7), S. 677-680, 2007.
• WU Chao, JIANG Xi-Ling, SHEN Hong-Wu und YU Ai-Ming: "Effects of CYP2D6 Status on Harmaline Metabolism, Pharmacokinetics and Pharmacodynamics, and a Pharmacogenetics-Based Pharmacokinetic Model", Biochem Pharmacol., Vol. 78(6), S. 617–624, September 15, 2009.
• ZETLER G. :"Der Harmin-Tremor und seine Antagonisten", Arch.experm. Path. Pharmak., 231, 34 (1957)

Toxizitaet:

• MAHMOUDIAN M. et al.: "Toxicity of Peganum harmala: Review and a Case Report", Iranian Journal of Pharmacology & Therapeutics (IJPT), Vol 1, No 1, (2002).
• JIMENEZ Judith, RIVERON-NEGRETE Leticia, ABDULLAEV Fikrat, ESPINOSA-AGUIRRE Javier, RODRIGUEZ-ARNAIZ Rosario: "Cytotoxicity of the beta-carboline alkaloids harmine and harmaline in human cell assays in vitro", Experimenltal and Toxicologic Pathology: 60 (2008) S. 381-389.

MAO-Hemmung:

• BAUMBACHER Gordon, HANSEN Mary Susan: "Abuse of Monoamine Oxidase Inhibitors", Drug Alcohol Abuse, 18(4), S. 399-406 (1992).
• BRUSH D. Eric, BIRD Steven B. and BOYER Edward W.: "Monoamine Oxidase Inhibitor Poisoning Resulting from Internet Misinformation on Illicit Substances", Journal of Toxicology, Clinical Toxicology, Vol. 42, No. 2, S. 191–195, 2004.
• COZZI Nicholas Vito et al.: "Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter.", J. Neurol. Transm., (2009), 116: S. 1591-1599.
• GRACIE and ZARKOV: "Three Beta-Carboline Containing Plants as Potentiators of Synthetic DMT and Other Indole Psychedelics"
• HALBERSTADT Adam L. et al.: "Modification of the effects of 5-methoxy-N,N-dimethyltryptamine on exploratory behavior in rats by monoamine oxidase inhibitors", Psychopharmacology (Berl). 2008 November; 201(1): S. 55–66.
• HERRAIZ Tomas, CHAPARRO Carolina: "Human monoamine oxidase enzyme inhibition by coffee and B-carbolines norharman and harman isolated from coffee", Life Sciences: Vol. 78 (2006): S. 795 -802.
• LESSIN A. W., LONG R. F. und PARKES M. W.: "The Central Stimulant Properties of some Substituted Indolylalkylamines and b-Carbolines and their Activities as Inhibitors of Monoamine Oxidase and the Uptake of 5-Hydroxytryptamine", Br. J. Pharmac. Chemother., Vol. 29, S. 70-79, 1967.
• MARTIN-IVERSON Mathew T., YAMADA Naoto, BY Arnold W., LODGE Bruce A.: "Designer" Amphetamines: Effects on Behavior and Monoamines With or Without Reserpine and/or a-Methyl-para-tyrosine Pretreatment", Journal of Psychiatry & Neuroscience, VoL 16, No. 5, 1991.
• MCKENNA Dennis J. et al.: "Monoamine Oxidase Inhibitors in South American Hallucinogenic Plants Part 2: Constituents of Orally-Active Myristicaceous Hallucinogens", Journal of Ethnopharmacology, 12 (1984) 179-211.
• OTT Jonathan: "Pharmahuasca: On Phenethylamines and Potentiation.", MAPS - Volume 6 Number 3 Summer 1996 - S. 32-34, 1996.
• RIBA Jordi et al.: "Human Pharmacology of Ayahuasca: Subjective and Cardiovascular Effects, Monoamine Metabolite Excretion, and Pharmacokinetics", The Journal of Pharmacology and Experimental Therapeutics, 306:73–83, 2003.
• SAMOYLENKOA Volodymyr et al.: "Banisteriopsis caapi, a unique combination of MAO inhibitory and antioxidative constituents for the activities relevant to neurodegenerative disorders and Parkinson’s disease", J. Ethnopharmacol. 2010 February 3; 127(2): S. 357–367.
• SMILKSTEIN Martin J., SMOLINSKE Susan C., RUMACK Barry H.: "A Case of MAO Inhibitor/MDMA Interaction: Agony after Ecstasy.", Clinical Toxicology, 25(1&2), S. 149-159 (1987).
• YRITIAA Mercedes et al.: "Determination of N,N-dimethyltryptamine and b-carboline alkaloids in human plasma following oral administration of Ayahuasca", Journal of Chromatography B, 779 (2002) 271–281.